Bold reveal: a new combination therapy may outperform traditional chemotherapy for AML, offering longer chances of staying cancer-free and a better quality of life during treatment. But here's where it gets controversial... could this shift redefine the standard of care for more patients soon? And this is the part most people miss: the strongest results came from a specific patient group, and broader applicability will require careful evaluation.
A recent trial compared azacitidine–venetoclax (aza-ven) with conventional intensive induction chemotherapy in adults newly diagnosed with acute myeloid leukemia (AML). The aza-ven regimen, already the preferred option for older patients unfit for intensive therapy, was tested against the standard induction approach for those still considered fit for aggressive treatment. The study met its primary goal by showing a significant improvement in event-free survival (EFS) with aza-ven. Additionally, younger patients eligible for intensive chemotherapy experienced higher overall response rates and greater rates of composite complete response when treated with aza-ven compared with induction chemotherapy. Importantly, more patients in the aza-ven arm proceeded to transplant after responding, with fewer early deaths, better initial quality of life, and less time spent in the hospital.
The trial enrolled 172 adults who were randomly assigned to either aza-ven or standard intensive chemotherapy. Event-free survival was the primary endpoint, defined as time to relapse, disease progression, refractoriness prompting a change in therapy, or death. With a median follow-up of just under 22 months, the aza-ven group achieved a median EFS of over 14 months, versus just over 6 months for the intensive-chemotherapy group. After adjusting for other variables, the benefit of aza-ven remained, and at the one-year mark, 53% of aza-ven patients were event-free compared with 36% in the control group.
The study applied to patients with intermediate- to high-risk AML, excluding those with core binding factor fusions, FLT3 mutations, or NPM1 mutations in patients under 60 (these exclusions shape the population studied). As a result, while the findings are compelling for a substantial subset of AML patients who can tolerate intensive therapy, they do not automatically extend to all AML subtypes without further focused research.
Dr. Amir Fathi, the study's lead author and a leukemia expert at Mass General Brigham Cancer Institute, noted, “The data support using this regimen in this population, including adverse-risk and intermediate-risk patients who do not have FLT3 mutations. This does not necessarily rule out benefits for other groups, but their outcomes require dedicated studies.”
Key outcomes favored aza-ven:
- Higher overall response rate: 88% vs 62%
- Higher composite complete response: 78% vs 54%
- Greater transplant uptake: 61% vs 40%
- Similar rates of severe treatment-related adverse events between groups
- No aza-ven deaths within 60 days vs. 5% in the induction group
- Shorter hospitalizations and fewer ICU admissions in the aza-ven arm
- Improved early quality of life and lower symptom burden, including less depression, at two weeks
These results herald potential changes in AML treatment paths, especially for patients who can tolerate intensive therapy. However, ongoing analyses will compare costs, infection risks, measurable residual disease status, and other factors to refine when and for whom aza-ven offers the most value ahead of transplant decisions.
The study was investigator-initiated, with Genentech and AbbVie Inc. providing the study drug and funding for research staff. The presentation is scheduled for December 7, 2025, at the Plenary Scientific Session.
What this could mean for you or a loved one depends on individual disease features, risk category, and fitness for intensive chemotherapy. If you have thoughts or questions about how aza-ven might fit into a specific AML scenario, share them in the comments to foster a broader, thoughtful discussion.
%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg)
